Sigmapharm to appeal Pfizer and BMS’ Eliquis win
03-09-2020
BMS partners with drug accelerator to launch biotech
05-02-2020
Bristol-Myers Squibb to acquire Celgene in $74bn deal
03-01-2019
Katherine Welles / Shutterstock.com
Bristol Myers Squibb (BMS) has announced a deal to acquire protein engineering company Forbius, including its portfolio of protein inhibitors.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Bristol Myers Squibb, BMS, Forbius, oncology, TGF-beta, AVID200, cancer, Celgene, inhibitor
